Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

National Vision Hlds

Henry Schein

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.

3 MedTech Stocks Likely to Top Estimates This Earnings Season

Johnson & Johnson

UnitedHealth Group

Everyone seems to be focused on the Nasdaq, as tech stocks lead the way higher. While that may be the case, we've seen soaring healthcare stocks too.

Buckle Up! 3 Healthcare Stocks Set to Soar to New Heights

Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?

Apple

AbbVie

Arbor Realty Trust

Abbott Labs

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

Amazon

American Express

Bank of America

Becton, Dickinson and Co.

Blackrock Inc

Bristol-Myers

Citigroup

Caterpillar

Cisco Systems

CVS Health

Chevron

Disney

Digital Realty Trust

Duke Energy

Emerson Electric

Enterprise Products Partners

Eaton

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summarizes Q2 of 2023 and focuses on goals, current holdings, allocation, sales, and buys.

My Dividend Growth Portfolio - Q2 2023 Summary

IRVING, Texas--(BUSINESS WIRE)-- #ACOs--Lightbeam Health Solutions, the leader in population health enablement solutions and services, today announces an expanded collaboration to deliver more solutions via Cardinal Health™ Navista™ TS, a suite of technology solutions developed to help community oncologists improve outcomes and costs associated with patient treatment for value-based care models. The Enhancing Oncology Model (EOM) replaced the Oncology Care Model (OCM) in July 2023. As such, participati.

Lightbeam Health Expands Agreement with Cardinal Health to Advance Enhancing Oncology Model Initiatives

ORLANDO, Fla.--(BUSINESS WIRE)--Transaction Data Systems (TDS), a portfolio company of BlackRock Long Term Private Capital and GTCR, is pleased to announce the closing of the previously announced transaction with Cardinal Health (NYSE: CAH) to merge with Outcomes. This merger brings together a full suite of patient engagement, clinical and pharmacy workflow solutions to the nation's largest network of retail, chain, and grocery pharmacies. The company will assume the name Outcomes and fully reb.

Transaction Data Systems Announces Closing of Merger with Outcomes™

Shares of Cardinal Health Inc. CAH, -0.30% were down 1% premarket on Monday after analysts at Evercore ISI downgraded the stock to an in-line rating, from outperform previously. The healthcare services company's share valuation now fully reflects its improving fundamentals and potential upside, the analysts wrote in a research note Monday.

Cardinal Health shares fall after downgrade

DUBLIN, Ohio , July 5, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2023 on August 15, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2023 on August 15

Agilent Technologies

Agree Realty

Ameren

Federal Agricultural

Albemarle

Allstate

Allegion

Air Products and Chemicals

Alexandria Real Estate Equities

Atrion

Broadcom

Axis Capital

Booz Allen Hamilton Hld

Brookfield Asset Management

BancFirst

Baxter

Franklin Resources

Brookfield Renewable Partners

Bank of Nova Scotia

Cadence Bank

Crown Castle International

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Dividend Champion, Contender, And Challenger Highlights: Week Of June 25

Essential Properties Realty Trust Inc

Lennox International

National Fuel Gas

National HealthCare

Realty Income Corp

Schwab US Dividend Equity ETF

TowneBank

W. P. Carey

Dividend increases typically indicate strong business performance and a commitment to rewarding shareholders. The article provides a list of companies with at least five years of consistent dividend growth and upcoming dividend increases. They have an average increase of 2.9% and a median increase of 2.5%.

9 Upcoming Dividend Increases Including A Dividend King

Automatic Data Processing

A. O. Smith

C.H. Robinson Worldwide

Cincinnati Financial

Clorox

Cintas Corp

Expeditors International of Washington

Genuine Parts

W.W. Grainger

Illinois Tool Works

Kimberly-Clark

Lowe's

McDonald's

Procter & Gamble

Sherwin-Williams

Sysco

Walmart

Exxon Mobil

Return on Capital Employed (ROCE) is a financial ratio that measures a company's profitability and efficiency in utilizing its capital to generate returns. Strategies that focus on investing in companies with high ROCE or significant improvements in ROCE have historically outperformed the overall market. ROCE should be incorporated into stock research as it is an important metric for evaluating the long-term performance of a business.

Using Return On Capital Employed To Generate Alpha With Dividend Aristocrats

News for Cardinal Health Stock (CAH)